MétaCan
Menu
Back to cohort
Record W4405828684 · doi:10.1177/1877718x241300295

Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies

2024· article· en· W4405828684 on OpenAlexaff
David Devos, Olivier Rascol, Wassilios G. Meissner, Alexandra Foubert‐Samier, Simon J.G. Lewis, Christine Tranchant, Mathieu Anheim, David Maltête, Philippe Rémy, Karla Eggert, Heidi Pape, Christian Gény, Philippe Couratier, Camille Carroll, Ray Sheridan, David J. Burn, Nicola Pavese, Jason Raw, Daniela Berg, Oksana Suchowersky, Lorraine V. Kalia, Andrew Evans, Sophie Drapier, Téodor Danaila, Alfons Schnitzler, Jean-Christophe Corvol, Gilles Defer, Noemi Toiber Temin, Caroline Fradette, Fernando Tricta, Caroline Moreau

Bibliographic record

VenueJournal of Parkinson s Disease · 2024
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsToronto Western HospitalUniversity Health NetworkUniversity of Alberta
FundersSanofi GenzymeHorizon 2020 Framework ProgrammeSun PharmaSunovionH. Lundbeck A/SBoston Scientific CorporationEVER Neuro PharmaIpsenCentre Hospitalier Universitaire de ToulouseServierAcorda TherapeuticsInstitut National de la Santé et de la Recherche MédicaleEuropean CommissionAssociation France ParkinsonAgence Nationale de la RechercheParkinson's UKChiesi USAAlexion PharmaceuticalsTeva Pharmaceutical IndustriesPfizerBiogenMedtronicSanofiAllerganAstraZenecaDirection de l’hospitalisation et de l’offre de SoinsEli Lilly and CompanyBristol-Myers Squibb
KeywordsDeferiproneParkinson's diseaseMedicineDiseaseInternal medicineDeferoxamine

Abstract

fetched live from OpenAlex

BackgroundReducing nigrostriatal iron overload reduces neuronal loss in Parkinson's disease (PD) models.ObjectiveExamine the safety and efficacy of deferiprone in reducing motor disability progression in dopaminergic-treated and treatment-naïve patients with early-stage PD.MethodsTwo phase II, multicenter studies, SKY and EMBARK, enrolled patients diagnosed with early PD (<3 years from screening). In SKY, patients on stable dopaminergic therapy were randomized 1:1 to one of four dosage (or placebo-matching) cohorts (300, 600, 900, 1200 mg twice daily [BID]) for 9 months. EMBARK enrolled patients on stable dopaminergic therapy or treatment-naïve patients and received 15 mg/kg BID. For both studies, the primary outcome was the change from baseline to month 9 in motor examination score (Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III). ClinicalTrials.gov: NCT02728843; ANZCTR: ACTRN12617001578392.ResultsOverall, 140 patients were randomized in SKY (28 per cohort). Thirty-six patients enrolled in EMBARK (27 dopaminergic-treated; 9 treatment-naïve). In the SKY study, all doses showed the same worsening as the placebo group, with the exception of the 600 mg dose, which was associated with non-significant reductions in MDS-UPDRS Part III least-squares mean (LSM) between baseline and 9 months (-2-8 points versus placebo). In EMBARK, LSM (SE) changes from baseline in MDS-UPDRS Part III were nonsignificant (-1.6 [1.7]) and significant (8.3 [3.9]) for dopaminergic-treated and treatment-naïve patients, respectively, the latter indicating disease worsening. Adverse events possibly related to deferiprone were reported in 35.7%-88.9% across all deferiprone groups vs. 42.9% for placebo.ConclusionsSKY and EMBARK studies indicate that deferiprone combined with L-dopa does not provide significant motor function benefit, while the absence of L-dopa treatment worsens symptoms.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.229
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.324
Teacher spread0.286 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Parkinson s DiseaseSame topicParkinson's Disease Mechanisms and TreatmentsFrench-language works237,207